Tyler Reese, MD, AAHIVS
Assistant Professor of Clinical Medicine
Medical Director, Inpatient Addiction Consult Team at UI Health
Department of Medicine, Division of Academic Internal Medicine and Geriatrics
Email:
Notable Honors
2025, Ruth Fox Scholarship, American Society of Addiction Medicine
2024, Addiction Medicine Advocacy Conference Scholarship, American Society of Addiction Medicine
Education
Undergraduate: Environmental Public Health, The Ohio State University, Columbus, OH
Medical School: Loyola University Chicago Stritch School of Medicine, Maywood, IL
Residency: Internal Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO
Fellowship: Addiction Medicine, Rush University Medical Center, Chicago, IL
Research Currently in Progress
Dr. Reese's research focuses on HIV prevention, infectious diseases, substance use, and public health. He was awarded a National Institutes of Health (NIH) National Heart, Lung, and Blood Institute T35 Research Grant for his published work on obesity and global public health. He also co-authored the first published case report describing an outbreak of medetomidine-associated opioid overdoses in Chicago, Illinois, in May 2024.
Dr. Reese currently serves as a Sub-Investigator for Merck's Phase 3 EXPrESSIVE-11 trial (MK-8527-011; ClinicalTrials.gov Identifier: NCT07044297), which is evaluating the efficacy and safety of once-monthly oral MK-8527 for HIV-1 pre-exposure prophylaxis (PrEP).
In addition, Dr. Reese serves as the UIC co-lead for the Adolescent Trials Network (ATN) for HIV/AIDS Interventions. His research activities include ATN 173, a study evaluating the effectiveness of doxycycline post-exposure prophylaxis (Doxy-PEP) in preventing bacterial sexually transmitted infections among adolescent and young adult females, and ATN 166, which is evaluating an integrated mobile health (mHealth) and telehealth intervention to improve PrEP engagement and adherence among young queer men.